Abstract

Mini Review

A Mini Review of Newly Identified Omicron Sublineages

Dasaradharami Reddy K*, Anusha S and Palem Chandrakala

Published: 18 December, 2023 | Volume 7 - Issue 3 | Pages: 066-076

The ongoing COVID-19 pandemic has seen the evolution of the SARS-CoV-2 virus, resulting in the emergence of various concerning variants with unique biological characteristics. As the pandemic continues, it will be crucial to promptly evaluate the potential of any new variant to cause severe illness. The severity of the latest Omicron sublineages, including BA.5, XBB, BQ.1.18, BA.2, BA.2.75, and EG.5.1, is currently under assessment. This system provides valuable and essential information for rapidly assessing the threat posed by new versions of the virus.

Read Full Article HTML DOI: 10.29328/journal.acr.1001082 Cite this Article Read Full Article PDF

Keywords:

COVID-19; Concerning variants; Omicron sublineages

References

  1. Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J; COVID-19 Genomics UK Consortium; Peacock SJ, Barclay WS, de Silva TI, Towers GJ, Robertson DL. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023 Mar;21(3):162-177. doi: 10.1038/s41579-022-00841-7. Epub 2023 Jan 18. PMID: 36653446; PMCID: PMC9847462.
  2. Tracking SARS-CoV-2 Variants. 2022. https://www.who.int/activities/tracking-SARS-CoV-2- variants.
  3. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, Subramoney K, Makatini Z, Moyo S, Amoako DG, Baxter C, Althaus CL, Anyaneji UJ, Kekana D, Viana R, Giandhari J, Lessells RJ, Maponga T, Maruapula D, Choga W, Matshaba M, Mbulawa MB, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022 Sep;28(9):1785-1790. doi: 10.1038/s41591-022-01911-2. Epub 2022 Jun 27. PMID: 35760080; PMCID: PMC9499863.
  4. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, Anyaneji UJ, Bester PA, Boni MF, Chand M, Choga WT, Colquhoun R, Davids M, Deforche K, Doolabh D, du Plessis L, Engelbrecht S, Everatt J, Giandhari J, Giovanetti M, Hardie D, Hill V, Hsiao NY, Iranzadeh A, Ismail A, Joseph C, Joseph R, Koopile L, Kosakovsky Pond SL, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022 Mar;603(7902):679-686. doi: 10.1038/s41586-022-04411-y. Epub 2022 Jan 7. PMID: 35042229; PMCID: PMC8942855.
  5. Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, Rakshit P, Singh S, Abraham P, Panda S, Team N. SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. Microorganisms. 2021 Jul 20;9(7):1542. doi: 10.3390/microorganisms9071542. PMID: 34361977; PMCID: PMC8307577.
  6. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell TW, Tully DC, Washburne AD, Wenseleers T, Gimma A, Waites W, Wong KLM, van Zandvoort K, Silverman JD; CMMID COVID-19 Working Group; COVID-19 Genomics UK (COG-UK) Consortium; Diaz-Ordaz K, Keogh R, Eggo RM, Funk S, Jit M, Atkins KE, Edmunds WJ. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021 Apr 9;372(6538):eabg3055. doi: 10.1126/science.abg3055. Epub 2021 Mar 3. PMID: 33658326; PMCID: PMC8128288.
  7. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, de Oliveira T. Continued emergence and evolution of Omicron in South Africa: New BA. 4 and BA. 5 lineages.  2022; 2022-05.
  8. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera G, O'Toole Á, Amato R, Ragonnet-Cronin M, Harrison I, Jackson B, Ariani CV, Boyd O, Loman NJ, McCrone JT, Gonçalves S, Jorgensen D, Myers R, Hill V, Jackson DK, Gaythorpe K, Groves N, Sillitoe J, Kwiatkowski DP; COVID-19 Genomics UK (COG-UK) consortium; Flaxman S, Ratmann O, Bhatt S, Hopkins S, Gandy A, Rambaut A, Ferguson NM. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021 May;593(7858):266-269. doi: 10.1038/s41586-021-03470-x. Epub 2021 Mar 25. PMID: 33767447.
  9. Callaway E. What Omicron's BA.4 and BA.5 variants mean for the pandemic. Nature. 2022 Jun;606(7916):848-849. doi: 10.1038/d41586-022-01730-y. PMID: 35750920.
  10. Brüssow H. COVID-19: Omicron - the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. Microb Biotechnol. 2022 Jul;15(7):1927-1939. doi: 10.1111/1751-7915.14064. Epub 2022 Apr 20. PMID: 35443078; PMCID: PMC9111164.
  11. Dhama K, Nainu F, Frediansyah A, Yatoo MI, Mohapatra RK, Chakraborty S, Zhou H, Islam MR, Mamada SS, Kusuma HI, Rabaan AA, Alhumaid S, Mutair AA, Iqhrammullah M, Al-Tawfiq JA, Mohaini MA, Alsalman AJ, Tuli HS, Chakraborty C, Harapan H. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. J Infect Public Health. 2023 Jan;16(1):4-14. doi: 10.1016/j.jiph.2022.11.024. Epub 2022 Nov 19. PMID: 36446204; PMCID: PMC9675435.
  12. Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature. 2021 Dec;600(7887):21. doi: 10.1038/d41586-021-03552-w. PMID: 34824381.
  13. Taylor CA, Whitaker M, Anglin O, Milucky J, Patel K, Pham H, Chai SJ, Alden NB, Yousey-Hindes K, Anderson EJ, Teno K, Reeg L, Como-Sabetti K, Bleecker M, Barney G, Bennett NM, Billing LM, Sutton M, Talbot HK, McCaffrey K, Havers FP; COVID-NET Surveillance Team. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):466-473. doi: 10.15585/mmwr.mm7112e2. PMID: 35324880; PMCID: PMC8956338.
  14. Mohapatra RK, Kandi V, Sarangi AK, Verma S, Tuli HS, Chakraborty S, Chakraborty C, Dhama K. The recently emerged BA.4 and BA.5 lineages of Omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic - Correspondence. Int J Surg. 2022 Jul;103:106698. doi: 10.1016/j.ijsu.2022.106698. Epub 2022 Jun 8. PMID: 35690362; PMCID: PMC9176102.
  15. Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Target Ther. 2022 Apr 28;7(1):141. doi: 10.1038/s41392-022-00997-x. PMID: 35484110; PMCID: PMC9047469.
  16. Callaway E. Are COVID surges becoming more predictable? New Omicron variants offer a hint. Nature. 2022 May;605(7909):204-206. doi: 10.1038/d41586-022-01240-x. PMID: 35523871.
  17. Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, Wang J, Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X, Du S, Zhang Z, Hao X, Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022 Feb;602(7898):657-663. doi: 10.1038/s41586-021-04385-3. Epub 2021 Dec 23. PMID: 35016194; PMCID: PMC8866119.
  18. Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, Nehlmeier I, Graichen L, Moldenhauer AS, Winkler MS, Lier M, Dopfer-Jablonka A, Jäck HM, Behrens GMN, Pöhlmann S. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 2022 Feb 3;185(3):447-456.e11. doi: 10.1016/j.cell.2021.12.032. Epub 2021 Dec 24. PMID: 35026151; PMCID: PMC8702401.
  19. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, Metzler M, Kohmer N, Hoehl S, Marschalek R, Herrmann E, Helfritz FA, Wolf T, Goetsch U, Ciesek S. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. EBioMedicine. 2022 Aug;82:104158. doi: 10.1016/j.ebiom.2022.104158. Epub 2022 Jul 11. PMID: 35834885; PMCID: PMC9271884.
  20. Carrazco-Montalvo A, Herrera-Yela A, Alarcón-Vallejo D, Gutiérrez-Pallo D, Armendáriz-Castillo I, Andrade-Molina D, Muñoz-Mawyin K, Fernández-Cadena JC, Morey-León G, Usfq-Covid-Consortium, Crn Influenza Y Ovr-Inspi, Patiño L. Omicron Sub-Lineages (BA.1.1.529 + BA.*) Current Status in Ecuador. Viruses. 2022 May 28;14(6):1177. doi: 10.3390/v14061177. PMID: 35746651; PMCID: PMC9230377.
  21. Kumar S, Karuppanan K, Subramaniam G. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment. J Med Virol. 2022 Oct;94(10):4780-4791. doi: 10.1002/jmv.27927. Epub 2022 Jun 16. PMID: 35680610; PMCID: PMC9347785.
  22. Desingu PA, Nagarajan K, Dhama K. Emergence of Omicron third lineage BA.3 and its importance. J Med Virol. 2022 May;94(5):1808-1810. doi: 10.1002/jmv.27601. Epub 2022 Jan 23. PMID: 35043399; PMCID: PMC9015590.
  23. Mohapatra RK, Kandi V, Verma S, Dhama K. Challenges of the Omicron (B.1.1.529) Variant and Its Lineages: A Global Perspective. Chembiochem. 2022 May 4;23(9):e202200059. doi: 10.1002/cbic.202200059. Epub 2022 Mar 23. PMID: 35322516; PMCID: PMC9083815.
  24. Khandia R, Singhal S, Alqahtani T, Kamal MA, El-Shall NA, Nainu F, Desingu PA, Dhama K. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environ Res. 2022 Jun;209:112816. doi: 10.1016/j.envres.2022.112816. Epub 2022 Jan 29. PMID: 35093310; PMCID: PMC8798788.
  25. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, Subramoney K, Makatini Z, Moyo S, Amoako DG, Baxter C, Althaus CL, Anyaneji UJ, Kekana D, Viana R, Giandhari J, Lessells RJ, Maponga T, Maruapula D, Choga W, Matshaba M, Mbulawa MB, Msomi N; NGS-SA consortium; Naidoo Y, Pillay S, Sanko TJ, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022 Sep;28(9):1785-1790. doi: 10.1038/s41591-022-01911-2. Epub 2022 Jun 27. PMID: 35760080; PMCID: PMC9499863.
  26. Rahman S, Hossain MJ, Nahar Z, Shahriar M, Bhuiyan MA, Islam MR. Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic. Environ Health Insights. 2022 Oct 20;16:11786302221129396. doi: 10.1177/11786302221129396. PMID: 36299441; PMCID: PMC9585367.
  27. Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X, Yu Y, Wang P, Zhang Z, Liu P, An R, Hao X, Wang Y, Wang J, Feng R, Sun H, Zhao L, Zhang W, Zhao D, Zheng J, Yu L, Li C, Zhang N, Wang R, Niu X, Yang S, Song X, Chai Y, Hu Y, Shi Y, Zheng L, Li Z, Gu Q, Shao F, Huang W, Jin R, Shen Z, Wang Y, Wang X, Xiao J, Xie XS. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022 Aug;608(7923):593-602. doi: 10.1038/s41586-022-04980-y. Epub 2022 Jun 17. PMID: 35714668; PMCID: PMC9385493.
  28. Basky G, Vogel L. XE, XD & XF: what to know about the Omicron hybrid variants. CMAJ. 2022 May 9;194(18):E654-E655. doi: 10.1503/cmaj.1095998. PMID: 35534032; PMCID: PMC9259411.
  29. Chakraborty C, Bhattacharya M, Sharma AR, Dhama K. Recombinant SARS-CoV-2 variants XD, XE, and XF: The emergence of recombinant variants requires an urgent call for research - Correspondence. Int J Surg. 2022 Jun;102:106670. doi: 10.1016/j.ijsu.2022.106670. Epub 2022 May 13. PMID: 35569759; PMCID: PMC9098807.
  30. Mohapatra RK, Kandi V, Tuli HS, Chakraborty C, Dhama K. The recombinant variants of SARS-CoV-2: Concerns continues amid COVID-19 pandemic. J Med Virol. 2022 Aug;94(8):3506-3508. doi: 10.1002/jmv.27780. Epub 2022 Apr 27. PMID: 35419806; PMCID: PMC9088633.
  31. Rahimi F, Talebi Bezmin Abadi A. Hybrid SARS-CoV-2 variants. Int J Surg. 2022 Jun;102:106656. doi: 10.1016/j.ijsu.2022.106656. Epub 2022 May 6. PMID: 35533853; PMCID: PMC9074379.
  32. Roemer C, Hisner R, Frohberg N, Sakaguchi H, Gueli F, Peacock TP. SARS-CoV-2 Evolution, Post-Omicron. virological. org. 911.
  33. WHO: Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member states. 2022. https://www.who.int/docs/default-source/coronaviruse/technical-brief-and-priority-action-on-omicron.pdf?sfvrsn=50732953_3
  34. WHO, South Africa. 2021, 2022. https://covid19.who.int/region/afro/country/za
  35. WHO, Statement on Omicron sublineage BA.2, 2022. https://www.who.int/news/item/22–02-2022-statement-on-omicron-sublineage-ba.2
  36. CDC, Omicron variant: what you need to know. 2021, 2022. https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html
  37. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro Surveill. 2017 Mar 30;22(13):30494. doi: 10.2807/1560-7917.ES.2017.22.13.30494. PMID: 28382917; PMCID: PMC5388101.
  38. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall. 2017 Jan 10;1(1):33-46. doi: 10.1002/gch2.1018. PMID: 31565258; PMCID: PMC6607375.
  39. Westbrook J, Feng Z, Jain S, Bhat TN, Thanki N, Ravichandran V, Gilliland GL, Bluhm W, Weissig H, Greer DS, Bourne PE, Berman HM. The Protein Data Bank: unifying the archive. Nucleic Acids Res. 2002 Jan 1;30(1):245-8. doi: 10.1093/nar/30.1.245. PMID: 11752306; PMCID: PMC99110.
  40. Nextstrain: Nextstrain SARS-CoV-2 Resources on Nextstrain. 2021. https://nextstrain.org/sars-cov-2/
  41. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, Giattino C, Rodés-Guirao L. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021 Jul;5(7):947-953. doi: 10.1038/s41562-021-01122-8. Epub 2021 May 10. Erratum in: Nat Hum Behav. 2021 Jun 17;: PMID: 33972767.
  42. Coresearchers, CoVariants. 2021. https://covariants.org.
  43. CNCB-NGDC Members and Partners. Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2022. Nucleic Acids Res. 2022 Jan 7;50(D1):D27-D38. doi: 10.1093/nar/gkab951. PMID: 34718731; PMCID: PMC8728233.
  44. Zhao WM, Song SH, Chen ML, Zou D, Ma LN, Ma YK, Li RJ, Hao LL, Li CP, Tian DM, Tang BX, Wang YQ, Zhu JW, Chen HX, Zhang Z, Xue YB, Bao YM. The 2019 novel coronavirus resource. Yi Chuan. 2020 Feb 20;42(2):212-221. doi: 10.16288/j.yczz.20-030. PMID: 32102777.
  45. Sun Q, Shu C, Shi W, Luo Y, Fan G, Nie J, Bi Y, Wang Q, Qi J, Lu J, Zhou Y, Shen Z, Meng Z, Zhang X, Yu Z, Gao S, Wu L, Ma J, Hu S. VarEPS: an evaluation and prewarning system of known and virtual variations of SARS-CoV-2 genomes. Nucleic Acids Res. 2022 Jan 7;50(D1):D888-D897. doi: 10.1093/nar/gkab921. PMID: 34634813; PMCID: PMC8728250.
  46. Rodrigues CH, Pires DE, Ascher DB. DynaMut: predicting the impact of mutations on protein conformation, flexibility and stability. Nucleic Acids Res. 2018 Jul 2;46(W1):W350-W355. doi: 10.1093/nar/gky300. PMID: 29718330; PMCID: PMC6031064.
  47. Hammer Ø, Harper DA. Past: paleontological statistics software package for education and data analysis. Palaeontologia electronica. 2001; 4(1): 1.
  48. MathWorks Inc. MATLAB, High-performance Numeric Computation, and Visualization Software: User's Guide: for UNIX Workstations. MathWorks. 1992.
  49. Imai M, Iwatsuki-Horimoto K, Hatta M, Loeber S, Halfmann PJ, Nakajima N, Watanabe T, Ujie M, Takahashi K, Ito M, Yamada S, Fan S, Chiba S, Kuroda M, Guan L, Takada K, Armbrust T, Balogh A, Furusawa Y, Okuda M, Ueki H, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595. doi: 10.1073/pnas.2009799117. Epub 2020 Jun 22. PMID: 32571934; PMCID: PMC7368255.
  50. Chan JF, Zhang AJ, Yuan S, Poon VK, Chan CC, Lee AC, Chan WM, Fan Z, Tsoi HW, Wen L, Liang R, Cao J, Chen Y, Tang K, Luo C, Cai JP, Kok KH, Chu H, Chan KH, Sridhar S, Chen Z, Chen H, To KK, Yuen KY. Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility. Clin Infect Dis. 2020 Dec 3;71(9):2428-2446. doi: 10.1093/cid/ciaa325. PMID: 32215622; PMCID: PMC7184405.
  51. Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J, Morioka Y, Nao N, Nasser H, Uriu K, Kosugi Y, Tsuda M, Orba Y, Sasaki M, Shimizu R, Kawabata R, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sawa H, Ikeda T, Irie T, Matsuno K, Tanaka S, Fukuhara T, Sato K. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022 Mar;603(7902):700-705. doi: 10.1038/s41586-022-04462-1. Epub 2022 Feb 1. PMID: 35104835; PMCID: PMC8942852.
  52. Armando F, Beythien G, Kaiser FK, Allnoch L, Heydemann L, Rosiak M, Becker S, Gonzalez-Hernandez M, Lamers MM, Haagmans BL, Guilfoyle K, van Amerongen G, Ciurkiewicz M, Osterhaus ADME, Baumgärtner W. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. Nat Commun. 2022 Jun 20;13(1):3519. doi: 10.1038/s41467-022-31200-y. PMID: 35725735; PMCID: PMC9207884.
  53. Kimura I, Yamasoba D, Tamura T, Nao N, Suzuki T, Oda Y, Mitoma S, Ito J, Nasser H, Zahradnik J, Uriu K, Fujita S, Kosugi Y, Wang L, Tsuda M, Kishimoto M, Ito H, Suzuki R, Shimizu R, Begum MM, Yoshimatsu K, Kimura KT, Sasaki J, Sasaki-Tabata K, Yamamoto Y, Nagamoto T, Kanamune J, Kobiyama K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Shirakawa K, Takaori-Kondo A, Kuramochi J, Schreiber G, Ishii KJ; Genotype to Phenotype Japan (G2P-Japan) Consortium; Hashiguchi T, Ikeda T, Saito A, Fukuhara T, Tanaka S, Matsuno K, Sato K. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. Cell. 2022 Oct 13;185(21):3992-4007.e16. doi: 10.1016/j.cell.2022.09.018. Epub 2022 Sep 14. PMID: 36198317; PMCID: PMC9472642.
  54. Uraki R, Halfmann PJ, Iida S, Yamayoshi S, Furusawa Y, Kiso M, Ito M, Iwatsuki-Horimoto K, Mine S, Kuroda M, Maemura T, Sakai-Tagawa Y, Ueki H, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Pekosz A, Kandeil A, Webby RJ, Wang Z, Imai M, Suzuki T, Kawaoka Y. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature. 2022 Dec;612(7940):540-545. doi: 10.1038/s41586-022-05482-7. Epub 2022 Nov 2. PMID: 36323336.
  55. Uraki R, Iida S, Halfmann PJ, Yamayoshi S, Hirata Y, Iwatsuki-Horimoto K, Kiso M, Ito M, Furusawa Y, Ueki H, Sakai-Tagawa Y, Kuroda M, Maemura T, Kim T, Mine S, Iwamoto N, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Wang Z, Ohmagari N, Theiler J, Fischer W, Korber B, Imai M, Suzuki T, Kawaoka Y. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. Nat Commun. 2023 Mar 23;14(1):1620. doi: 10.1038/s41467-023-37059-x. PMID: 36959194; PMCID: PMC10035475.
  56. Tamura T, Ito J, Uriu K, Zahradnik J, Kida I, Anraku Y, Nasser H, Shofa M, Oda Y, Lytras S, Nao N, Itakura Y, Deguchi S, Suzuki R, Wang L, Begum MM, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Shimizu R, Tsuda M, Kosugi Y, Fujita S, Pan L, Sauter D, Yoshimatsu K, Suzuki S, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun. 2023 May 16;14(1):2800. doi: 10.1038/s41467-023-38435-3. PMID: 37193706; PMCID: PMC10187524.
  57. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature. 2022 Jul;607(7917):119-127. doi: 10.1038/s41586-022-04856-1. Epub 2022 May 16. PMID: 35576972; PMCID: PMC10579982.
  58. Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, Uriu K, Tsuda M, Zahradnik J, Shirakawa K, Suzuki R, Kishimoto M, Kosugi Y, Kobiyama K, Hara T, Toyoda M, Tanaka YL, Butlertanaka EP, Shimizu R, Ito H, Wang L, Oda Y, Orba Y, Sasaki M, Nagata K, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell. 2022 Jun 9;185(12):2103-2115.e19. doi: 10.1016/j.cell.2022.04.035. Epub 2022 May 2. PMID: 35568035; PMCID: PMC9057982.
  59. Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen IM, James W, Gordon S, Pepper MS. SARS-CoV-2 Variants, Vaccines, and Host Immunity. Front Immunol. 2022 Jan 3;12:809244. doi: 10.3389/fimmu.2021.809244. PMID: 35046961; PMCID: PMC8761766.
  60. Wu Y, Long Y, Wang F, Liu W, Wang Y. Emergence of SARS-CoV-2 Omicron variant and strategies for tackling the infection. Immun Inflamm Dis. 2022 Dec;10(12):e733. doi: 10.1002/iid3.733. PMID: 36444634; PMCID: PMC9639460.
  61. Yi H, Wang J, Wang J, Lu Y, Zhang Y, Peng R, Lu J, Chen Z. The Emergence and Spread of Novel SARS-CoV-2 Variants. Front Public Health. 2021 Aug 2;9:696664. doi: 10.3389/fpubh.2021.696664. PMID: 34409009; PMCID: PMC8364952.
  62. Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020 Mar 15;16(10):1753-1766. doi: 10.7150/ijbs.45134. PMID: 32226295; PMCID: PMC7098028.
  63. Yin J, Li C, Ye C, Ruan Z, Liang Y, Li Y, Wu J, Luo Z. Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants. Comput Struct Biotechnol J. 2022;20:824-837. doi: 10.1016/j.csbj.2022.01.026. Epub 2022 Jan 31. PMID: 35126885; PMCID: PMC8802458.

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?